Skip Navigation

Isavuconazole added to Adalvo Portfolio

27 September 2022

Adalvo is pleased to announce the addition of Isavuconazole Oral and Injectable forms to our product Portfolio. Dossier readiness for these products is expected in Q1 2024.

Our products are being developed in collaboration with one of our strategic partners, based on the reference brand CRESEMBA. Both products are indicated in the treatment of invasive aspergillosis and mucormycosis.

The brand sold approximately $325mio globally in 2021, having a significant growth potential with Global 3Y CAGR at 17%, according to IQVIA.

With our clearly defined product pathway, we believe Adalvo will be amongst the first wave of filers, and we expect to achieve day-1 launch in all major markets.

Adalvo expects to be one of the few companies able to offer both the vial and capsule forms.

Disclaimer: Isavuconazole which is subject to patent protection is currently not offered or made available in countries where patents are in force.